At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 44 enrolled
Drug / intervention
Tecovirimat +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects
In Brief
A Phase 4 clinical trial evaluating Tecovirimat, sevelamer carbonate oral tablet, and 3 other interventions for Smallpox. Completed, enrolled 44 participants across 1 site.
Detailed Summary
An open-label, drug-drug interaction study with TPOXX and phosphate binders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmallpox
CountriesUnited States
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJun 2022
Primary CompletionDec 2022
Study CompletionApr 2023
TodayJul 2026
First PostedJul 24, 2020
Enrollment StartJun 8, 2022
Primary CompletionDec 15, 2022
Study CompletionApr 23, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago
Interventions
Tecovirimatdrug
oral antiviral
sevelamer carbonate oral tabletdrug
phosphate binder
sucroferric oxyhydroxide chewable tabletdrug
phosphate binder
calcium acetate oral tabletdrug
phosphate binder
Lanthanum Carbonate Chewable Tabletdrug
phosphate binder